Skip to content
Screener

BioCryst Pharmaceuticals BCRX Q1 2026 earnings

Reported May 6, 2026 · Before market open

Revenue$156.4MBeat by $5.3M
EPS-$0.03Miss by $0.09
Revenue estimate$151.1M
EPS estimate$0.06

Next report

Nov 2, 2026 (in a month)
Revenue estimate$165.7M
EPS estimate$0.10

Financials

Q1 2026

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.39B+52.3%
Enterprise value$2.63B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Current ratio1.9×-1.0×

Segments

By segment

See full
Reportable Segment$156.4M+7.5%

FAQ

When did BioCryst Pharmaceuticals report Q1 2026 earnings?
BioCryst Pharmaceuticals (BCRX) reported Q1 2026 earnings on May 6, 2026 before market open.
What were BioCryst Pharmaceuticals's Q1 2026 revenue and EPS?
BioCryst Pharmaceuticals reported revenue of $156.4M and eps of $-0.03 for Q1 2026.
Did BioCryst Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $151.1M by $5.3M. EPS missed the consensus estimate of $0.06 by $0.09.
How did BioCryst Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.5% from $145.5M a year earlier.
Where can I find BioCryst Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001171843-26-002960) and the 10-Q periodic report (0001628280-26-031238) directly on SEC EDGAR. The filing index links above go to sec.gov.